Market Forecasts and Industry Analysis Global Spiramycin Base (Spiramycin) (CAS 8025-81-

Spiramycin Base Global Market Report 2017:
Radiant Insights, Inc
“This report mainly introduces volume and value
market share by players, by regions, by product
type, by consumers and also their price change
details.”
Spiramycin is a macrolide antibiotic and antiparasitic It is used to treat toxoplasmosis and
various other infections of soft tissues. Although used in Europe, Canada and Mexico, spiramycin is
still considered an experimental drug in the United States, but can sometimes be obtained by special
permission from the FDA for toxoplasmosis in the first trimester of pregnancy.
Spiramycin has been used in Europe since the year 2000 under the trade name "Rovamycine",
produced by Rhone-Poulenc Rorer and Famar Lyon, France and Eczacibasi Ilae, Turkey. It also goes
under the name Rovamycine in Canada (distributed by OdanLaboratories), where it is mostly
marketed to dentists for mouth infections.
Complete Report Available @ https://www.radiantinsights.com/research/global-
spiramycin-base-spiramycin-cas-8025-81-8-market-outlook-2016-2021
This report provides detailed analysis of worldwide markets for Spiramycin Base
(Spiramycin) (CAS 8025-81-8) from 2011-2015 and provides extensive market forecasts 2016-2021
by region/country and subsectors. It covers the key technological and market trends in the Spiramycin
Base (Spiramycin) (CAS 8025-81-8) market and further lays out an analysis of the factors influencing
the supply/demand for Spiramycin Base (Spiramycin) (CAS 8025-81-8), and the
opportunities/challenges faced by industry participants.
Follow Us: